Want to see IN:NECLIFE full AI Analyst Report?
Top Page
Nectar Lifesciences Ltd.
(NECLIFE)
Select Model
Select Model
Rating:48Neutral
Price Target:
₹11.00
▲(6.80% Upside)
Action:Reiterated
Date:08/27/26
The score is primarily weighed down by weak financial performance, highlighted by FY2026’s collapse in revenue, large losses, and significant cash burn that elevate funding and operational risk. Technicals provide some offset due to positive short-term momentum (price above key short-term averages and positive MACD), but overbought readings and a still-weak longer-term trend limit that support. Valuation remains unattractive due to negative earnings (negative P/E).
Positive Factors
Diversified Pharmaceutical Model
Exposure to APIs, finished formulations, and contract manufacturing or research gives Nectar Lifesciences multiple pharmaceutical revenue avenues. This breadth can support customer diversification and allow the company to participate across value-chain segments, although results still depend on execution and demand.
Negative Factors
Revenue Collapse
A reported collapse in annual revenue to zero represents a severe disruption to the operating business rather than ordinary volatility. Unless revenue recovers, the company lacks the scale needed to absorb fixed costs, support investment, or rebuild sustainable earnings over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Pharmaceutical Model
Exposure to APIs, finished formulations, and contract manufacturing or research gives Nectar Lifesciences multiple pharmaceutical revenue avenues. This breadth can support customer diversification and allow the company to participate across value-chain segments, although results still depend on execution and demand.
Read all positive factors
Nectar Lifesciences Ltd. (NECLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.14B
Dividend Yield20.72%
Average Volume (3M)35.24K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth-99.53%
EPS Growth-41.93%
CountryIN
Employees111
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-11.38
Shares Outstanding194,260,970
10 Day Avg. Volume19,141
30 Day Avg. Volume35,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)97.56
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nectar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing ...
How the Company Makes Money
Nectar Lifesciences Ltd. makes money primarily by selling pharmaceutical products to customers (typically including other pharmaceutical companies, distributors, and institutional buyers depending on the product category). Key revenue streams gene...
Nectar Lifesciences Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.43M | 20.11M | 16.70B | 16.84B | 15.24B | 16.69B |
| Gross Profit | -567.25M | -590.34M | 3.02B | 4.82B | 579.91M | 2.99B |
| EBITDA | 83.68M | -289.51M | -245.66M | 1.69B | 994.97M | 1.61B |
| Net Income | -2.45B | -2.93B | -1.14B | 49.95M | -241.83M | 250.47M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 6.22B | 20.47B | 21.91B | 21.89B | 23.91B |
| Cash, Cash Equivalents and Short-Term Investments | 1.25B | 1.25B | 272.63M | 203.01M | 178.94M | 182.35M |
| Total Debt | 0.00 | 0.00 | 5.82B | 6.36B | 7.54B | 8.60B |
| Total Liabilities | -5.82B | 393.11M | 10.91B | 11.22B | 11.25B | 13.03B |
| Stockholders Equity | 5.82B | 5.82B | 9.56B | 10.69B | 10.65B | 10.88B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | -3.61B | 1.26B | 1.95B | 1.04B | 700.35M |
| Operating Cash Flow | 1.53B | -3.49B | 1.69B | 2.25B | 1.34B | 950.05M |
| Investing Cash Flow | -82.31M | 12.08B | -419.30M | -170.25M | 517.04M | 166.44M |
| Financing Cash Flow | -1.58B | -7.67B | -1.28B | -2.05B | -1.86B | -1.19B |
Nectar Lifesciences Ltd. Technical Analysis
Negative
10.30
Price Trends
11.14
Negative
11.61
Negative
13.18
Negative
Market Momentum
<0.01
Positive
41.78
Neutral
13.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 10.3 is below the 20-day moving average (MA) of 11.82, below the 50-day MA of 11.14, and below the 200-day MA of 13.18, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 13.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.
Nectar Lifesciences Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹293.49B | 58.87 | ― | 0.15% | 78.33% | 182.61% | |
64 Neutral | ₹216.82B | 32.35 | ― | 0.20% | 24.83% | 36.88% | |
64 Neutral | ₹59.57B | 35.52 | ― | 0.49% | 18.56% | 60.06% | |
56 Neutral | ₹27.88B | -83.03 | ― | 0.27% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹35.61B | -1,325.09 | ― | 0.45% | 15.49% | -112.78% | |
48 Neutral | ₹2.14B | -0.96 | ― | 20.72% | -99.53% | -41.93% |
* General Sector Average
IN:NECLIFE
Nectar Lifesciences Ltd.
11.01
-4.71
-29.96%
IN:GRANULES
Granules India Limited
875.00
350.39
66.79%
IN:HIKAL
Hikal Limited
226.10
-35.96
-13.72%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
202.95
87.77
76.20%
IN:NEULANDLAB
Neuland Laboratories Ltd.
22,875.70
7,600.29
49.76%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
740.80
80.35
12.17%
Nectar Lifesciences Ltd. Corporate Events
Nectar Lifesciences Issues Revised AGM Proceedings, Receives Clean Audit for FY 2025-26
Sep 19, 2026
Nectar Lifesciences has issued revised proceedings for its 31st Annual General Meeting after correcting an inadvertent error in the cut-off date, reaffirming its adherence to SEBI listing regulations. The AGM was conducted on September 18, 2026 vi...
Nectar Lifesciences Publishes Q1 FY2026 Results in Press and Online
Aug 15, 2026
Nectar Lifesciences Ltd. has released its unaudited financial results for the quarter ended June 30, 2026, and circulated them through national daily Business Standard and Punjabi newspaper Desh Sewak. The company has also made detailed consolidat...
Nectar Lifesciences to Relocate Corporate Office Within Chandigarh Industrial Hub
Aug 15, 2026
The board of directors of Nectar Lifesciences Ltd. has approved the relocation of the company’s corporate office within Chandigarh’s Industrial Area Phase 1, moving from Plot No. 110 to the West Wing of Godrej Eternia, Plot No. 70, wit...
Nectar Lifesciences Monetizes Non-Core Jammu Unit With Asset Sale
Aug 4, 2026
Nectar Lifesciences Ltd. is an India-based pharmaceutical manufacturer of bulk drugs and allied products, with industrial operations anchored in Punjab and a corporate base in Chandigarh. Its business structure includes wholly owned units such as ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.